Thursday 29 April 2021

Primary Cell Culture Market To Hold a High Potential for Growth by 2028| Key participants Thermo Fisher, GE Healthineers

 

Primary Cell Culture Market Growth & Trends

The global primary cell culture market size is expected to reach USD 8.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.6% from 2021 to 2028. The market growth is owing to several factors such as advancement in genetic engineering, rising demand for regenerative medicines, and robust funding for cellular therapies development.

In addition, the growing focus on functional biology can be further attributed to the market growth. Several R&D investments for the development of novel solutions have increased the demand for culture medium. For instance, in April 2020, Sumitomo Chemical invested USD 30 million in Conagen a U.S.-based company. The investment was aimed at strengthening its alliance and developing high functional products as well as processes using synthetic biology.

Moreover, the ongoing COVID-19 pandemic has provided an opportunity for researchers to study and understand the new variants of the virus with the application of primary cell culture. The large pool of human cells from various genetic backgrounds and varied health conditions facilitated researchers to conduct experiments for thorough results. Various institutions have shown their support and interest in scientific research to match specialized cell culture media.

Request a free sample copy or view report summary: Primary Cell Culture Market Report

Primary Cell Culture Market Report Highlights

  • The reagents and supplements segment accounted for the largest revenue share in 2020 owing to their growing application for maintaining primary cell viability
  • The primary cells segment is expected to witness the fastest growth rate over the forecast period owing to the increasing research initiatives for cancer and rare diseases
  • The enzymatic degradation segment held the largest revenue share in 2020 due to the advantage of obtaining a high cellular yield through enzymatic disaggregation
  • The mechanical separation segment is expected to witness lucrative growth over the forecast period owing to its large adoption as it’s an inexpensive, quick, and easy method for disaggregation of cellular entities
  • The animal cells segment accounted for the largest revenue share in 2020 owing to rising applications for vaccine development
  • The human cells segment is expected to witness substantial growth over the forecast period as they are extensively used for preclinical and clinical analyses in cancer research
  • The vaccine production segment dominated the market in 2020 owing to the rising focus on the development of new vaccines targeting new infections such as COVID-19
  • The stem cell therapy segment is expected to witness the fastest CAGR over the forecast period owing to the growing number of studies for designing therapies for genetic disorders
  • North America held the largest revenue share in 2020. The growth of the market in this region is owing to intensive research for the development of new therapies
  • Companies operating in the market are launching new products for primary cell cultures. For instance, in January 2021, Lonza launched customizable and high-quality cryopreserved Leukopaks. It is a product derived from enriched leukapheresis, which contains high concentrations of peripheral blood mononuclear such as B and T cells, and monocytes

Access Press Release@ https://www.grandviewresearch.com/press-release/global-primary-cell-culture-market

Primary Cell Culture Market Segmentation

Grand View Research has segmented the global primary cell culture market based on product, separation methods, cell type, application, and region:

Primary Cell Culture Product Outlook (Revenue, USD Million, 2017 - 2028)

  • Primary Cells
    • Fat
    • Blood
    • Nerve
    • Bone
    • Endothelial
    • Skin
    • Muscle
    • Stem
    • Others
  • Reagents and Supplements
    • Attachment Solutions
    • Buffers and Salts
    • Freezing Media
    • Sera
    • Growth Factors and Cytokines
    • Other
  • Media
    • Fat Cells Media
    • Blood Cells Media
    • Nerve Cells Media
    • Bone Cells Media
    • Endothelial Cells Media
    • Skin Cells Media
    • Muscle Cells Media
    • Stem Cells Media
    • Others

Primary Cell Culture Separation Methods Outlook (Revenue, USD Million, 2017 - 2028)

  • Explant Method
  • Enzymatic Degradation
    • Trypsin
    • Collagenase
    • Protease
    • Pronase
    • Dispase
    • Hyaluronidase
    • Neuraminidase
    • Elastase
    • DNase
    • Papain
    • Accutase
    • Others
  • Mechanical Separation
  • Others

Primary Cell Culture Cell Type Outlook (Revenue, USD Million, 2017 - 2028)

  • Animal
  • Human

Primary Cell Culture Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Tissue Culture & Tissue Engineering
  • Vaccine Production
  • Gene Therapy and Regenerative Medicine
  • Toxicity Testing and Drug Screening
  • Cancer Research
  • Model System
  • Virology
  • Prenatal Diagnosis
  • Stem Cell Therapy
  • Others

Primary Cell Culture Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK.
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

List of Key Players of Primary Cell Culture Market

  • Thermo Fisher Scientific, Inc.
  • Lonza
  • Merck
  • Corning Incorporated
  • Danaher  
  • PromoCell GmbH
  • ATCC
  • FUJIFILM Irvine Scientific, Inc.
  • Mattek
  • Axol Bioscience Ltd.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Downstream Processing Market Expected to Witness a Sustainable Growth over 2028

 Downstream Processing Market Growth & Trends

The global downstream processing market size is expected to reach USD 69.6 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.9% from 2021 to 2028. The capacity requirements during the development of biologic drugs have changed over the past few years, wherein the demand for manufacturing high-volume products has shifted to developing small-volume, high potency products. This creates new avenues for single-use technologies.

As adoption of small-scale, single-use systems for process development and downstream processing is already high, evolutionary changes are expected in the area of single-use technologies for manufacturing small-volume, highly potent drugs. The development of novel film chemistries, closed systems, automation in clinical-scale single-use systems, and smart sensors are some noteworthy advancements in the field.

A rise in applications of downstream processing for the manufacture of biopharmaceuticals is expected to bring growth opportunities to the market. This has also led to an increase in strategic deals and development in the market. For instance, in February 2021, Evozyne, LLC collaborated with a leading rare disorders drug manufacturer for the manufacture and marketing of novel biopharmaceuticals for immune modulation.

Request a free sample copy or view report summary: Downstream Processing Market Report

Downstream Processing Market Report Highlights

  • Chromatography systems accounted for the largest revenue share of products owing to the high adoption of chromatography for biopharmaceutical purification
  • The advent of single-use chromatography systems that bring an 80.0% reduction of the use of water and chemicals for buffer has further increased the adoption of chromatography for downstream processing of bio-therapeutics
  • Filters are anticipated to grow at a lucrative rate. Efforts taken by key players to develop intelligent membranes for purification and separation fuels this growth 
  • Purification by chromatography accounted for the largest share of the global market, as it can be employed across all steps of a downstream process. The technique is also crucial in bioprocessing to obtain pure biologics  
  • Solid-liquid separation is anticipated to grow at the fastest rate owing to the use of filtration and chromatography techniques for efficient separation 
  • Antibiotic production dominated the revenue generation in 2020 owing to the wide use of antibiotics for the treatment of a variety of clinical disorders including infectious diseases and cancer
  • A rise in occurrences of antibiotic resistance also propels the industrial-scale development of novel antibiotic candidates
  • North America dominated the regional segment in 2020 owing to the local presence of large in-house biopharmaceutical manufacturing facilities
  • Asia Pacific registered the fastest growth rate owing to rise in contract development services in emerging Asian economies
  • Key players are investing in the bioprocessing of vaccines and therapies for COVID-19 to increase their market share
  • In October 2020, Thermo Fisher Scientific announced a USD 700 million investment in CAPEX to cater to COVID-related demand in the biopharma market

Access Press Release@ https://www.grandviewresearch.com/press-release/global-downstream-processing-market

Downstream Processing Market Segmentation

Grand View Research has segmented the global downstream processing market on the basis of product, technology, application, and region:

Downstream Processing Product Outlook (Revenue, USD Million, 2017 - 2028)

  • Chromatography Systems
  • Filters
  • Evaporators
  • Centrifuges
  • Dryers
  • Others

Downstream Processing Technique Outlook (Revenue, USD Million, 2017 - 2028)

  • Cell Disruption
  • Solid-liquid separation
    • Filtration
    • Centrifugation
  • Concentration
    • Evaporation
    • Membrane filtration
  • Purification by Chromatography
  • Formulation

Downstream Processing Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Antibiotic Production
  • Hormone Production
  • Antibodies Production
  • Enzyme Production
  • Vaccine Production

Downstream Processing Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK.
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa (MEA)
    • South Africa
    • UAE

List of Key Players of Downstream Processing Market

  • GE Healthcare
  • Merck KGaA
  • Sartorius Stedim Biotech S.A.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Repligen
  • 3M Company
  • Eppendorf AG
  • Boehringer Ingelheim International GmbH
  • Corning Corporation
  • Lonza Group Ltd
  • Dover Corporation
  • Ferner PLC
  • Ashai Kasei

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Clinical Oncology Next Generation Sequencing Market Growth in the Coming Years

 

Clinical Oncology NGS Market Growth & Trends

The global clinical oncology next generation sequencing market size is expected to reach USD 892.61 million by 2028 registering a CAGR of 14.70%, according to a new report by Grand View Research, Inc. Technological advancements in next-generation sequencing coupled with high adoption of companion diagnostics and personalized medicine drive the global market growth. 

In addition, a rise in the utility of next generation sequencing (NGS) for liquid biopsy is expected to increase revenue generation in the market. NGS is employed to sequence circulating tumor DNA (ctDNA) for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive monitoring of tumors.

Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression. For instance, in January 2021, Spectrum Solutions, LLC collaborated with the UCLA School of Dentistry on saliva-based NGS liquid biopsy research, which would be used for early diagnosis of Non-Small Cell Lung Cancer (NSCLC).

North America dominated the global market in 2020 owing to multiple initiatives taken by various government bodies in the region to screen and prevent cancer, such as Cancer Prevention and Control Research Network, a flagship program by the CDC. Asia Pacific is projected to be the fastest-growing regional market over the forecast period owing to continuous reforms in the pharmaceutical and life sciences industries in the region.

Key players in this market have undertaken strategic alliances to strengthen their market position. For example, in March 2020, Thermo Fisher Scientific signed an agreement with Janssen Biotech, Inc. for the development of CDx for tumor management. Under the agreement, Janssen Research & Development, LLC would validate multiple biomarkers to be used with Thermo Fisher's Oncomine Dx target test for identification of patients with NSCLC

Request a free sample copy or view report summary: Clinical Oncology NGS Market Report

Clinical Oncology NGS Market Report Highlights

  • Targeted sequencing & resequencing accounted for the largest market share in 2020 owing to the high adoption of targeted gene panels for oncology diagnostics
  • Moreover, the discovery of novel cancer biomarkers further boosts the development of targeted sequencing oncology panels
  • Whole-Genome Sequencing (WGS) is projected to register the fastest growth rate from 2021 to 2028 as the technology offers a complete genomic survey of the tumor genome
  • This helps in the generation of a detailed map of indels, copy number changes, Single Nucleotide Variations (SNV), and complex structural rearrangements with a single assay
  • Companion diagnostics is projected to be the fastest-growing application segment from 2021 to 2028 owing to the high adoption and benefits offered by the technology
  • Therefore, major market participants focus on innovative R&D in companion diagnostics to gain approval for novel tests
  • For instance, in August 2020, the FDA approved Guardant360 CDx assay; an NGS-based liquid biopsy CDx to identify Epidermal Growth Factor Receptor (EGFR) gene mutations in metastatic NSCLC

Access Press Release@ https://www.grandviewresearch.com/press-release/global-clinical-oncology-next-generation-sequencing-ngs-market

Clinical Oncology NGS Market Segmentation

Grand View Research has segmented the global clinical oncology next generation sequencing market on the basis of technology, workflow, application, end-use, and region:

Clinical Oncology NGS Technology Outlook (Revenue, USD Million, 2017 - 2028)

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing Centrifuges

Clinical Oncology NGS Workflow Outlook (Revenue, USD Million, 2017 - 2028)

  • Pre-Sequencing
  • Sequencing
  • Data Analysis

Clinical Oncology NGS Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Screening
    • Sporadic Cancer
    • Inherited Cancer
  • Companion Diagnostics
  • Other Diagnostics

Clinical Oncology NGS End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Hospitals
  • Clinics
  • Laboratories

Clinical Oncology NGS Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK.
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia

List of Key Players of Clinical Oncology NGS Market

  • Illumina, Inc.
  • Thermo Fisher Scientific
  • Hoffmann-La Roche Ltd.
  • Agilent Technologies
  • Myriad Genetics
  • Beijing Genomics Institute (BGI)
  • Perkin Elmer
  • Foundation Medicine
  • Pacific Bioscience
  • Oxford Nanopore Technologies Ltd.
  • Paradigm Diagnostics
  • Caris Life Sciences
  • Partek, Inc.
  • Eurofins Scientific S.E.
  • Qiagen N.V.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Hospital Gowns Market is Estimated To Attain $8.26 Billion by 2028

 Hospital Gowns Market Growth & Trends

The global hospital gowns market size is expected to reach USD 8.26 billion by 2028 registering a CAGR of 12.8%, according to a new report by Grand View Research, Inc. The rising incidence of Hospital Acquired Infections (HAIs) and increasing number of surgical procedures are the key driving factors for the market growth. The recent outbreak of Covid-19 is also anticipated to have a significant impact on market growth.

The global pandemic has drastically increased the demand for medicines, emergency supplies, and hospital equipment including gowns, antiseptics, and disinfectant products. Covid-19 is a zoonotic virus and bats were considered to be the key reservoir of the virus. The intermediate host has not been identified yet and transmission has mainly taken place through fomites & droplets during close unprotected contact between infector & infected. Till now airborne transmission of the virus has not been reported. Thus, increasing hospital admissions across the globe have increased the demand for hospital gowns.

The WHO has appealed to industries and governments to increase the manufacturing of Personal Protective Equipment (PPE), including hospital gowns, gloves, medical masks, face shields, aprons, respirators, and goggles, by 40% to meet the increasing global demand. It also reported that the rise in demand for these accessories has increased their prices to a major extent. For instance, the price of surgical masks has increased six-fold and the price of hospital gowns has increased two-fold.

Request a free sample copy or view report summary: Hospital Gowns Market Report

Hospital Gowns Market Report Highlights

  • In terms of revenue, the surgical gowns segment held the largest share in 2020 owing to the rising incidents of chronic diseases and increasing number of surgical procedures
  • The reusable gowns segment is anticipated to witness the fastest growth over the forecast period owing to the increasing cases of Covid-19
  • The high-risk hospital gowns segment held the largest share in 2020 owing to the increased demand across the globe
  • Asia Pacific is expected to be the fastest-growing regional market over the forecast period owing to the increasing cases of diabetic foot ulcers and rising number of surgical procedures

Access Press Release@ https://www.grandviewresearch.com/press-release/global-hospital-gowns-market

Hospital Gowns Market Segmentation

Grand View Research has segmented the global hospital gowns market on the basis of type, usability, risk type, and region:

Hospital Gowns Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Surgical
  • Non-surgical
  • Patient

Hospital Gowns Usability Outlook (Revenue, USD Million, 2016 - 2028)

  • Disposable Gowns
    • Low
    • Average
    • Premium
  • Reusable Gowns
    • Low
    • Average
    • Premium

Hospital Gowns Risk Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Minimal
  • Low
  • Moderate
  • High

Hospital Gowns Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK.
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • Saudi Arabia

List of Key Players of Hospital Gowns Market

  • Medline Industries, Inc.
  • Standard Textile Co., Inc.
  • Angelica
  • AmeriPride Services, Inc.
  • 3M
  • Cardinal Health

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Wednesday 28 April 2021

Biopharmaceutical Excipients Market Projected to Register 6.5% CAGR from 2021 to 2028: Grand View Research Inc.

 

Biopharmaceutical Excipients Market Growth & Trends

The global biopharmaceutical excipients market size is expected to reach USD 3.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The factors driving the market growth include increasing development of biosimilars, instability associated with drugs & vaccines, and growing focus on the development of novel drugs, among others.

The changing regulatory scenarios by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have impacted drug development. Several legislative proposals are addressing new ways for lowering the cost of prescription drugs. Similarly, in recent years there is an increasing focus on drug-manufacturing quality has led to several recalls by FDA and the EMA. Hence, the stringent investigations related to an examination of drugs are likely to promote the use of specific excipients for developing efficient drugs.

In addition, companies are collaborating with government authorities for increasing the application of novel compounds. For instance, in December 2019, U.S. FDA started a pilot program to evaluate novel biopharmaceutical excipients. Later, the initiative was supported by several companies such as AstraZeneca, Regeneron, and Janssen for FDA’s plan to review novel biopharmaceutical excipients. Regeneron highlighted different novel compounds that can potentially help in improving public health for example hydrophobic salts can reduce the viscosity of highly concentrated antibody formulations.

Moreover, the rising focus on the rapid development of COVID-19 vaccines and therapeutic drugs is further driving the market growth. Excipients have an essential role in the development of biologics as it helps in stabilizing the drug during storage and processing. The use of appropriate biopharmaceutical excipients enables the development of novel therapies and robust pharmaceutical products for fighting against the pandemic.

Large-scale pharmaceutical companies signed a long-term supply agreement with companies for supporting the development of COVID-19 vaccines. For instance, in November 2020, Pfizer Inc. signed a five-year contract with Croda International for lipid-based excipients that will be used for manufacturing Pfizer’s COVID-19 vaccine candidate. Similarly, in May 2020, Moderna signed a supply agreement with CordenPharma for the large-scale production of lipid excipient for the development of mRNA-1273, Moderna's COVID-19 vaccine candidate.

Request a free sample copy or view report summary: Biopharmaceutical Excipients Market Report

Biopharmaceutical Excipients Market Report Highlights

  • Carbohydrates accounted for the largest revenue share of 36.2% in 2020 owing to the increasing use of carbohydrates owing to their several advantages
  • The advantages include it helps the efficient binding of tablet ingredients, enables accurate dosing and protecting the tablet from harsh environmental conditions, among others
  • Sucrose amongst the carbohydrates dominated with a market share of 32.8% owing to its increasing application in stabilizing proteins
  • Starch is expected to witness the fastest CAGR of 6.6% from 2021 to 2028 owing to the increasing launch of new starch excipients
  • For instance, in May 2019, Colorcon Inc. launched STARTAB, a new starch tableting excipient. It is developed by directly compressible starch for enhancing the stability of moisture sensitive API
  • North America has emerged as the highest revenue-generating region, representing a market share of 32.0% in 2020
  • Large pharmaceutical companies are entering in collaboration with the companies in the region which can be attributed to market growth
  • For instance, in February 2020, MilliporeSigma entered in an agreement with ReForm Biologics LLC for commercializing ReForm’s excipients that are used in biotherapeutic formulations
  • In Asia Pacific, the market is expected to witness a lucrative CAGR of 7.0% from 2021 to 2028 owing to the increasing production of biosimilar drugs in the region
  • The government in this region is promoting biosimilar development. For instance, the government of South Korea provided regulatory guidance to local biosimilars companies for aiming to develop around 22.0% of global biosimilarsby 2020

Access Press Release@ https://www.grandviewresearch.com/press-release/global-biopharmaceutical-excipients-market

Biopharmaceutical Excipients Market Segmentation

Grand View Research has segmented the global biopharmaceutical excipients market on the basis of product and region:

Biopharmaceutical Excipients Product Outlook (Volume, Tonnes; Revenue, USD Million, 2017 - 2028)

  • Solubilizers & Surfactants/Emulsifiers
    • Triglycerides
    • Esters
    • Others
  • Polyols
    • Mannitol
    • Sorbitol
    • Others
  • Carbohydrates
    • Sucrose
    • Dextrose
    • Starch
    • Others
  • Specialty Excipients

Biopharmaceutical Excipients Regional Outlook (Volume, Tonnes; Revenue, USD Million, 2017 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK.
  • Asia Pacific
    • Japan
    • China
    • India
    • Malaysia
    • South Korea
    • Philippines
    • New Zealand
    • Australia
    • Singapore
    • Indonesia
  • Latin America
    • Brazil
  • Middle East & Africa
    • South Africa

List of Key Players of Biopharmaceutical Excipients Market

  • Merck KGaA
  • Signet Excipients Pvt. Ltd
  • Sigachi Industries Limited
  • Associated British Foods plc
  • Spectrum Chemical Manufacturing Corp.
  • Roquette Frères
  • IMCD
  • Clariant
  • DFE Pharma
  • Colorcon
  • BASF SE
  • Evonik Industries AG
  • RETTENMAIER & SĂ–HNE GmbH + Co KG

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Biopharmaceutical Third Party Logistics Market Size Is Expected To Reach $145.2 Billion By 2028

 

Biopharmaceutical 3PL Market Growth & Trends

The global biopharmaceutical third party logistics market size is expected to reach USD 145.2 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.6% from 2021 to 2028. Rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the market growth. The rising adoption of automated storage and retrieval systems in emerging countries is an ongoing trend in pharmaceutical logistics companies that has gained significant traction.

The biopharmaceutical third party logistic players played a vital role in the fight against COVID-19 by minimizing supply disruptions and prioritizing critical care drugs. The future also seems good for the biopharmaceutical 3PL market with rising demand for domestic logistics coupled with favorable government initiatives and policies.

Furthermore, the trend of shifting from small molecule drugs to biopharmaceuticals, mainly vaccines & biologics, is projected to drive the market. Since these small molecule drugs are temperature-sensitive products, demand for temperature-controlled transportation and storage increases and thus is responsible for market growth.

Additionally, environmental concerns and cost have caused a slight shift in the means of transport used for commercial products, moving from airway to seaway shipping, and in roadways from trucks to intermodal (both rail and truck). Intermodal transport is majorly used by these pharmaceutical companies to reduce the carbon footprint. The ongoing trend shows that pharmaceutical manufacturers have shifted towards sea freight to reduce the cost and risk factors. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Request a free sample copy or view report summary: Biopharmaceutical Third Party Logistics Market Report

Biopharmaceutical 3PL Market Report Highlights

  • In 2020, non-cold chain logistics held the largest market share of 80.8% in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control
  • The cold chain logistics segment is expected to register the faster CAGR of 8.6% over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
  • Warehousing and storage held the largest market of 43.6% share among the types of services in 2020
  • Asia Pacific is expected to emerge with the fastest CAGR of 7.2% over the forecast period owing to the adoption of medicines from the aging population and a shift of drug sales from brand manufacturers to generic

Access Press Release@ https://www.grandviewresearch.com/press-release/global-biopharmaceutical-third-party-logistics-3pl-market

Biopharmaceutical 3PL Market Segmentation

Grand View Research has segmented the global biopharmaceutical 3PL market on the basis of the supply chain, service type, and region:

Biopharmaceutical Third Party Logistics Supply Chain Outlook (Revenue, USD Billion, 2016 - 2028)

  • Cold Chain
  • Non-cold Chain

Biopharmaceutical Third Party Logistics Service Type Outlook (Revenue, USD Billion, 2016 - 2028)

  • Transportation
    • Air Freight
    • Sea Freight
    • Overland
  • Warehousing and Storage
  • Others

Biopharmaceutical Third Party Logistics Regional Outlook (Revenue, USD Billion, 2016 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK.
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

List of key players in the Biopharmaceutical 3PL Market

  • DHL International GmbH
  • SF Express
  • United Parcel Service of America, Inc.
  • AmerisourceBergen Corporation
  • DB Schenker
  • KUEHNE + NAGEL
  • Kerry Logistics Network Limited
  • Agility

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Next-Generation Sequencing Data Analysis Market to Witness Tremendous Growth and Expansion by 2028

 Next-Generation Sequencing Data Analysis Market Growth & Trends

The global next-generation sequencing data analysis market size is expected to reach USD 1.72 billion by 2028 registering a CAGR of 15.02%, according to a new report by Grand View Research, Inc. Key drivers contributing to market expansion include the growing adoption of sequencing platforms for clinical diagnosis because of a significant reduction in the cost of installation. The easy availability of genomic and proteomic data is also expected to create lucrative growth opportunities in this market during the forecast period.

In addition, a decrease in the cost of sequencing is expected to increase the adoption of next-generation sequencing (NGS), which, in turn, is likely to boost the market growth. Availability of tools, such as Agilent’s HaloPlex capture system and Targeted Methyl-Seq platform from EpiGentek Group Inc., has helped in the determination of DNA methylation profiles in individual genomes. An increase in the adoption of bisulfite-methylation for targeted sequencing and targeted methylation NGS data analysis methods is anticipated to propel market growth.

EpigenDx, CD Genomics, Novogene Co., Ltd., and Epigentek Group, Inc. are the key players that offer methylation sequencing and targeted bisulfite sequencing data analysis services. The launch of new products will further boost revenue generation in the market. Major market participants have undertaken various strategic initiatives to strengthen their position in the market. For instance, in January 2021, Transnetyx, Inc. collaborated with One Codex to provide end-to-end analysis and microbiome sequencing services. This is expected to offer affordable sequencing analysis services to researchers.

Request a free sample copy or view report summary: Next-Generation Sequencing Data Analysis Market Report

Next-Generation Sequencing Data Analysis Market Report Highlights

  • Services dominated the products segment in 2020 and will retain the leading position growing at the fastest CAGR during the forecast period
  • Although NGS is advantageous in terms of affordability and speed, many research entities are unable to adopt it owing to a lack of sufficient computational infrastructure and skilled professionals to analyze the generated information
  • Therefore, institutions that lack provision for data interpretation, analysis, and management adopt platforms & services offered by other companies in the market
  • Tertiary analysis occupied a major portion of the revenue generated by the workflow segment as it accounts for the most complex and important step of Next-Generation Sequencing, which is directly linked with the interpretation of results
  • In-house mode dominated the market in 2020 and is expected to maintain its dominance during the forecast period
  • However, the outsourced mode is expected to register the fastest CAGR from 2021 to 2028 owing to the time and cost benefits associated with this mode and the presence of key players offering data analysis services
  • The short-read sequencing segment led the global market in 2020 due to the wide adoption of these techniques as they are inexpensive and can work with fragment DNA along with the availability of several tools and algorithms
  • The academic research end-use segment generated the largest revenue in 2020; however, clinical research is estimated to be the fastest-growing segment from 2021 to 2028
  • North America dominated the global market in 2020 owing to the launch of large-scale genome sequencing projects and the rise in demand for personalized medicine

Access Press Release@ https://www.grandviewresearch.com/press-release/global-next-generation-sequencing-ngs-data-analysis-market

Next-Generation Sequencing Data Analysis Market Segmentation

Grand View Research has segmented the global next-generation sequencing data analysis market on the basis of product, workflow, mode, read length, end-use, and region:

Next-Generation Sequencing Data Analysis Product Outlook (Revenue, USD Million, 2017 - 2028)

  • Services
  • NGS Commercial Software
    • Platform OS/UI
    • Analytical Software
      • Alignment Tools & Software
        • DNA Seq Alignment
        • RNA Seq Alignment
        • Protein Seq Alignment
      • QC/Pre-processing Tools
      • Others

Next-Generation Sequencing Data AnalysisWorkflow Outlook (Revenue, USD Million, 2017 - 2028)

  • Primary
  • Secondary
    • Read Mapping
    • Variant Alignment & Variant Calling
  • Tertiary
    • Variant Annotation
    • Application-specific
      • Targeted Sequencing/Gene Panel
      • Exome Sequencing
      • RNA Sequencing
      • Whole Genome Sequencing
      • ChIP-sequencing
      • Others

Next-Generation Sequencing Data AnalysisMode Outlook (Revenue, USD Million, 2017 - 2028)

  • In-house
  • Outsourced

Next-Generation Sequencing Data AnalysisRead Length Outlook (Revenue, USD Million, 2017 - 2028)

  • Short Read
  • Long Read
  • Very Long Read

Next-Generation Sequencing Data AnalysisEnd-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other Users

Next-Generation Sequencing Data Analysis Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK.
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East Africa (MEA)
    • South Africa
    • Saudi Arabia

List of Key Players of Next-Generation Sequencing (NGS) Data Analysis Market

  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Illumina, Inc.
  • Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • PierianDx
  • Intrexon Bioinformatics Germany GmbH
  • Partek, Inc.
  • Eurofins Scientific
  • Pacific Biosciences of California, Inc.
  • DNASTAR, Inc.
  • Congenica Ltd.
  • Fabric Genomics, Inc.
  • Genuity Science
  • DNAnexus Inc.
  • SciGenom Labs Pvt. Ltd.
  • Golden Helix, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Nephrology & Urology Devices Market is Predicted to Hit a Steady 6.6% CAGR through 2028

 

Nephrology And Urology Devices Market Growth & Trends

The global nephrology and urology devices market size is anticipated to reach USD 7.21 billion by 2028 registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Unhealthy lifestyle and rise in smoking & alcohol consumption along with dietary irregularities are some of the factors resulting in urological and nephrological disorders. This is anticipated to increase the demand for devices to treat these disorders.

Increasing cases of Chronic Kidney Disease (CKD) are expected to boost the market growth. According to the National Kidney Foundation 2019, it is estimated that there are more than 2 million cases of CKD across the globe and this number continues to grow at a rate of 5-7% per year. Moreover, the growing adoption of minimally invasive procedures is expected to drive market growth.

Numerous non-invasive techniques have been introduced in the market, such as condom catheter, Doppler ultrasound video urodynamic, Intravesical Prostatic Protrusion (IPP), and penile cuff, which helps avoid painful catheterization. Technological advancements play a crucial role in driving market growth. For instance, certain companies introduced antimicrobial catheters to reduce catheter-associated infections and cases of thrombosis. Palindrome HSI heparin-coated & silver ion antimicrobial catheter by Medtronic PLC helps reduce clot formation and microbial colonization on the catheter surface.

Request a free sample copy or view report summary: Nephrology And Urology Devices Market Report

Nephrology And Urology Devices Market Report Highlights

  • On the basis of product, the others segment dominated the market in 2020 with the share of 28.49%
  • This growth can be attributed to the high prevalence of urological & nephrological disorders globally and the launch of technologically advanced products by the key players in this segment
  • However, the Percutaneous Nephrostomy (PCN) catheters segment is expected to register the fastest CAGR of 7.6% from 2021 to 2028 due to the increasing application scope of PCN in various kidney-related medical conditions
  • North America dominated the market with the highest revenue share of 33.20% in 2020 and will retain the leading position throughout the forecast period
  • The presence of prominent players, advanced healthcare infrastructure, and high public funding in the healthcare system are some of the factors responsible for the region’s growth

Access Press Release@ https://www.grandviewresearch.com/press-release/global-nephrology-urology-devices-market

Nephrology And Urology Devices Market Segmentation

Grand View Research has segmented the global nephrology and urology devices market on the basis of product and region:

Nephrology & Urology Devices Product Outlook (Revenue, USD Million, 2016 - 2028)

  • Ureteral Catheters
  • PCN Catheters
  • Urinary Stents
  • Stone Basket
  • Urology Guidewires
  • Renal Dilators
  • Others

Nephrology & Urology Devices Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • UK.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE

List of Key Players of Nephrology And Urology Devices Market

  • Medtronic plc
  • Fresenius Medical Care AG & Co. KGaA
  • Baxter International, Inc.
  • Boston Scientific Corp.
  • R. Bard, Inc.
  • Cook Group, Inc.
  • Hollister, Inc.
  • Nipro Corp.
  • Terumo Corp.
  • Coloplast A/S
  • ConvaTec Group plc
  • Braun AG
  • Teleflex, Inc.
  • Asahi Kasei Corp.
  • Nxstage Medical, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research    reports, customized research reports, and consulting services. To help clients make informed business    decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Intravenous Solutions Market is Expected to Reach a Value of $18.9 Billion by 2028

 

IV Solutions Market Growth & Trends

The global intravenous solutions market size is expected to reach USD 18.9 billion by 2028 according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.9% from 2021 to 2028. The growing incidence rate of chronic diseases such as cancer, increase in the number of premature births, and shortage of I.V. solutions in the U.S. are some of the key factors expected to drive the market.

One of the prime areas wherein intravenous (IV) fluids find usage is severe dehydration. Severe dehydration is seen in diseases such as diarrhea, resulting in the depletion of fluids from the body. According to the WHO, in 2017, diarrhea was the second leading cause of death in children under 5 years of age with around 5,25,000 lives lost each year. Intravenous (IV) fluids can play a key role in the treatment and prevention of deaths caused due to the dehydration/fluid loss associated with diarrhea. Other cases where intravenous fluids find application include surgeries and emergency situations.

The ongoing COVID-19 pandemic is expected to have a positive impact on the market. Intensive Care Units (ICU) worldwide are either operating at full capacity or are overcrowded due to the high influx of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As per an article published by BBC, in January 2021, critical care wards across England were running in full capacity. Nutritional care is one of the essential elements in managing these patients. This has increased the demand for intravenous (IV) fluids, as many of the patients, especially the elderly population are placed on ventilators and are unable to consume food orally.

Request a free sample copy or view report summary: IV Solutions Market Report

IV Solutions Market Report Highlights

  • The Total Parenteral Nutrition (TPN) segment led the segment in terms of revenue share in 2020 owing to its growing applications in the management of chronic diseases
  • The increasing number of surgeries and post-operative nutritional management is a prime factor driving the vitamins and minerals (salt and electrolyte) segment’s growth
  • North America dominated the market with a revenue share of nearly 40.8% in 2020 due to the high usage of IV fluids in the U.S.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-intravenous-iv-solutions-market

IV Solutions Market Segmentation

Grand View Research has segmented the global IV solutions market based on type, nutrients, and region:

Intravenous Solutions Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Total Parenteral Nutrition (TPN)
  • Peripheral Parenteral Nutrition (PPN)

Intravenous Solutions Nutrients Outlook (Revenue, USD Million, 2016 - 2028)

  • Carbohydrates
  • Single Dose Amino Acid Solution
  • Vitamins & Minerals (Salt and electrolyte)
  • Parenteral Lipid Emulsion
  • Others

Intravenous Solutions Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • UK.
    • Germany
    • France
    • Russia
    • Switzerland
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

List of Key Players of IV Solutions Market

  • Hospira
  • Terumo Corporation
  • Braun Melsungen AG
  • Fresenius Kabi
  • Baxter

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Enteral Feeding Formulas Market to Incur Meteoric Growth During 2021 to 2028: Grand View Research Inc.

 Enteral Feeding Formulas Market Growth & Trends

The global enteral feeding formulas market size is expected to reach USD 9.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.9% from 2021 to 2028. The growing prevalence of chronic diseases such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes is projected to drive the demand for products that support patients with oral intake issues. In addition, the rise in preterm births is one of the significant factors boosting the demand for enteral feeding formulas to meet the nutritional requirements of newborns.

Based on product, the standard formulas segment dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a vast variety of standard formulas coupled with increased demand for low-cost nutrient formulations. In addition, the demand with respect to standard tube feeds is significant among the volume-sensitive patients or the patients on fluid restrictions. Such conditions include renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

In 2020, based on flow type, the intermittent feeding flow type segment accounted for the highest revenue share in the market because intermittent feeding has shown better tolerance in patients as compared to bolus feeding. Moreover, this type of feeding does not require feeding pumps, which is helpful in allowing greater mobility in between the feedings. This is expected to increase its adoption among the hospital as well as homecare settings, thereby affirmatively impacting the segment growth.

In 2020, based on stage, the adults' segment accounted for the highest revenue share of 88.4% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The rising adoption of tube feeds in adults is one of the crucial factors driving the growth. In addition, the availability of large number of tube feeds or products for adults on a commercial level also contributes to the large share held by the segment. Glucerna, Osmolite, TwoCal, Vital, Promote, and Jevity are some of the popular brands by Abbott Nutrition for adults.

Based on indications, other indications, followed by cancer care accounted for the largest share in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote market growth. For instance, according to GLOBOCON 2020, there were around 19.3 million new cases of cancer worldwide in 2020. Europe accounted for about 23.4% of total cancer cases and Asia had the highest population suffering from cancer, which was about 60%.

In 2020, based on end user, the homecare segment accounted for the highest revenue share in the market and this segment is projected to witness the fastest CAGR over the forecast period. The increasing number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition is one of the key factors contributing to the growth of this segment. For instance, according to a recent survey conducted in the U.K., there were 187 patients on home enteral tube feeding out of the total 257 patients. This suggested that approximately 72% of patients were on home enteral tube feeding.

North America dominated the market with a revenue share of 29.7% in 2020 owing to the growing burden of chronic diseases such as diabetes, cancer, and other neurological conditions. Furthermore, increasing preference for home-based enteral therapy has decreased the number of patient visits to hospitals and clinics. In addition, increasing malnutrition is expected to further boost the demand for enteral feeding formulas in this region.

In addition, the rising number of COVID-19 cases in various geographies coupled with the large geriatric population, susceptible to various health conditions, are among the factors contributing to the growth of the market. For instance, according to an article published in Europe PMC in 2020, enteral nutrition is generally preferred over parenteral nutrition for COVID-19 patients admitted to the ICUs. In addition, it should be provided within 48 hours of admission. Hence, such instances signify increasing adoption of enteral feeding formulas during the pandemic.

Request a free sample copy or view report summary: Enteral Feeding Formulas Market Report

Enteral Feeding Formulas Market Report Highlights

  • The market is anticipated to grow over the forecast period owing to the growing prevalence of chronic diseases and the rise in preterm births
  • The standard formulas segment dominated the market in 2020, owing to the availability of a wide variety of standard formulas coupled with increased demand for low-cost nutrient formulations
  • The intermittent feeding flow segment dominated the market in 2020, owing to better tolerance in patients shown by intermittent flow as compared to bolus feeding
  • Adults accounted for the largest revenue share in the market in 2020 owing to the rising adoption of tube feeds in the adults and the availability of a large number of tube feeds or products for adults on the commercial level
  • Other indications followed by cancer care accounted for the largest share in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote market growth
  • The homecare segment accounted for the highest revenue share in the market owing to the rising number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition
  • North America dominated the market with a revenue share of 29.7% in 2020 owing to the growing burden of chronic diseases such as diabetes, cancer, and other neurological conditions

Access Press Release@ https://www.grandviewresearch.com/press-release/global-enteral-feeding-formulas-market

Enteral Feeding Formulas Market Segmentation

Grand View Research has segmented the global enteral feeding formulas market based on product, flow type, stage, indications, end-user, and region:

Enteral Feeding Formulas Product Outlook (Revenue, USD Million, 2014 - 2028)

  • Standard formula
  • Disease-specific formula

Enteral Feeding Formulas Flow Type Outlook (Revenue, USD Million, 2014 - 2028)

  • Intermittent feeding flow
  • Continuous feeding flow

Enteral Feeding Formulas Stage Outlook (Revenue, USD Million, 2014 - 2028)

  • Adult
  • Pediatric

Enteral Feeding Formulas Indication Outlook (Revenue, USD Million, 2014 - 2028)

  • Alzheimer’s
  • Nutrition Deficiency
  • Cancer Care
  • Diabetes
  • Chronic Kidney Diseases
  • Orphan Diseases
  • Dysphagia
  • Pain Management
  • Malabsorption/GI Disorder/Diarrhea
  • Others

Enteral Feeding Formulas End-user Outlook (Revenue, USD Million, 2014 - 2028)

  • Hospitals
    • Cardiology
    • Neurology
    • Critical Care (ICU)
    • Oncology
    • Others
  • Home Care

Enteral Feeding Formulas Regional Outlook (Revenue, USD Million, 2014 - 2028)

  • North America
    • US.
    • Canada
  • Europe
    • UK.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
  • Asia Pacific
    • Australia
    • China
    • Japan
    • South Korea
    • India
    • Singapore
    • New Zealand
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

List of Key Players of Enteral Feeding Formulas Market

  • Abbott
  • Danone SA
  • Fresenius Kabi
  • NestlĂ©
  • Victus, Inc.
  • Primus Pharmaceuticals, Inc.
  • Meiji Holdings. Co., Ltd.
  • Rickett Benckiser Group Plc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Protein Ingredients Market Expected to Witness a Sustainable Growth over 2030: Grand View Research Inc.

  Protein Ingredients Market Growth & Trends The global  protein ingredients market  size is expected to reach USD 85.5 billion by 2028,...